Dr. Flynn Discusses Ibrutinib for Hematologic Malignancies

Joseph M. Flynn, DO, MPH
Published Online: Monday, July 28, 2014
Joseph M. Flynn, DO, MPH, co-director, Division of Hematology; co-director, LIVESTRONG Survivorship Center of Excellence; medical director, James Survivorship Clinics, The Ohio State University, James Cancer Hospital, discusses the impact ibrutinib has had on treating hematologic malignancies.

Flynn says the approval of ibrutinib is one of the most exciting discoveries in the last two decades. In CLL, this drug has changed the way that patients can be treated following relapse. This agent is well tolerated in most patients but physicians typically avoid giving this agent to patients taking blood thinners, Flynn says.

Some mutations that may be associated with resistance to ibrutinib have been identified. Hopefully, Flynn says, this will allow physicians with a better sense of who to target.

Online CME Activities
Free CME from PER
9th Annual Multidisciplinary Symposium on Head and Neck Cancer® Medical Crossfire®
Clinical Challenges in the Management of Melanoma
Advances in ImmunoOncology: Intralesional Oncolytic Immunotherapy in Melanoma
Updates in the Treatment of Lung Cancer
More Reading
$auto_registration$